Splicing-Associated Diseases

  • Splicing-associated diseases are disorders caused by abnormalities in RNA splicing, the biological process through which introns are removed and exons are joined to produce mature messenger RNA (mRNA). Accurate splicing is essential for generating functional transcripts and maintaining normal gene expression. Errors in this process can alter protein sequences, disrupt protein production, or change the amount of functional protein available in cells. Because many human genes contain multiple exons and undergo alternative splicing, even small changes in splicing regulation can have significant biological consequences.
  • Splicing abnormalities can arise from mutations in genes that encode proteins or RNA molecules involved in the splicing machinery, as well as from mutations within the genes being spliced. Variants affecting canonical splice donor and acceptor sites, branch points, polypyrimidine tracts, and regulatory sequences can interfere with normal splice-site recognition. Mutations in exonic or intronic splicing enhancers and silencers may also alter the recruitment of splicing factors. These changes can cause exon skipping, intron retention, use of alternative splice sites, or activation of cryptic splice sites that are not normally used.
  • Several molecular mechanisms connect abnormal splicing with disease. Exon skipping may remove an essential protein domain or change the reading frame, potentially introducing a premature termination codon. Intron retention can disrupt translation or lead to degradation of the abnormal transcript. Aberrant splice-site selection may produce shortened, extended, or structurally altered proteins. Some abnormal transcripts contain premature termination codons and are eliminated through nonsense-mediated mRNA decay (NMD), a cellular surveillance pathway that reduces the accumulation of potentially harmful transcripts. In other cases, abnormal transcripts escape degradation and produce dysfunctional or harmful proteins.
  • Splicing-associated diseases include inherited genetic disorders, cancers, neurological diseases, muscular disorders, blood disorders, and developmental conditions. Spinal muscular atrophy (SMA) is a well-known example involving the SMN2 gene, in which alternative splicing frequently results in exclusion of exon 7 and reduced production of functional survival motor neuron protein. Duchenne muscular dystrophy can result from mutations that disrupt the reading frame of the DMD gene, sometimes through abnormal splicing, leading to a severe deficiency of functional dystrophin. In beta-thalassemia, mutations affecting splice sites or regulatory sequences in the HBB gene can reduce or prevent the production of normal beta-globin. Some forms of retinitis pigmentosa are associated with mutations in genes encoding spliceosomal components, including PRPF31, PRPF8, and SNRNP200.
  • Abnormal RNA splicing is also a major feature of cancer. Mutations in genes encoding spliceosome components, including SF3B1, SRSF2, and U2AF1, have been identified in several hematological malignancies and other cancers. These mutations can change the selection of splice sites across many genes, producing abnormal transcript isoforms that influence cell proliferation, differentiation, apoptosis, and genome stability. Cancer-associated splicing changes may also affect genes involved in tumor suppression, oncogenic signaling, immune regulation, and drug resistance. Consequently, abnormal splicing can contribute to cancer development and progression and may provide useful diagnostic or therapeutic targets.
  • Neurological and neurodegenerative disorders can also involve altered splicing regulation. The nervous system depends heavily on alternative splicing to produce cell-specific protein isoforms required for neuronal development, synaptic function, and communication between neurons. Changes in splicing factors or RNA-binding proteins can disturb these processes. For example, abnormal RNA processing is associated with amyotrophic lateral sclerosis (ALS), frontotemporal dementia, and certain forms of myotonic dystrophy. In myotonic dystrophy, expanded nucleotide repeats can disrupt the activity of muscleblind-like (MBNL) proteins and cause widespread mis-splicing of transcripts in muscle and other tissues.
  • Bioinformatics plays an important role in identifying and understanding splicing-associated diseases. Genomic sequencing data can be examined to detect variants affecting splice donor sites, acceptor sites, branch points, and regulatory regions. Whole-genome sequencing (WGS) and whole-exome sequencing (WES) can identify candidate genetic variants, while RNA sequencing (RNA-seq) provides direct evidence of their effects on transcript processing. RNA-seq analysis can reveal exon skipping, intron retention, alternative splice-site usage, abnormal splice junctions, and changes in transcript abundance.
  • Computational splice-site prediction tools help evaluate whether genetic variants are likely to alter normal splicing. Tools such as SpliceAI, MaxEntScan, NNSplice, and Human Splicing Finder can predict changes in splice-site strength or identify potential cryptic splice sites. SpliceAI uses deep learning to predict the effects of genetic variants on RNA splicing, including the gain or loss of splice sites. These predictions help prioritize candidate variants for further investigation, although computational predictions alone do not establish that a variant causes disease.
  • RNA-seq analysis tools are used to characterize abnormal splicing events and quantify their frequency. STAR and HISAT2 support splice-aware alignment, while rMATS, MAJIQ, SUPPA2, LeafCutter, and Whippet can identify and quantify different types of alternative splicing events. StringTie and Salmon can assist with transcript reconstruction and isoform quantification. Differential splicing analysis compares transcript processing between healthy and affected samples to identify disease-associated changes. Visualization methods, including sashimi plots, help researchers examine exon coverage and splice-junction read support.
  • The interpretation of splicing-associated variants requires integration of genomic, transcriptomic, and functional evidence. A predicted splice-disrupting variant should ideally be evaluated using RNA evidence to determine whether abnormal transcripts are produced. Relevant evidence may include altered exon inclusion, intron retention, abnormal splice junctions, reduced transcript abundance, or changes in protein expression. Gene expression databases, transcript annotation resources, genome browsers, and clinical variant databases can support interpretation. Important resources include Ensembl, RefSeq, GTEx, ClinVar, dbSNP, and the Human Gene Mutation Database (HGMD). Tissue-specific expression information is particularly important because splicing patterns can differ considerably between tissues and developmental stages.
  • Experimental validation is essential for confirming the biological consequences of predicted splicing abnormalities. Reverse transcription polymerase chain reaction (RT-PCR) can detect changes in exon inclusion or intron retention, while quantitative PCR (qPCR) can measure transcript abundance. Sanger sequencing of RT-PCR products can confirm abnormal splice junctions. Minigene assays provide a controlled system for testing the effects of specific variants on splicing, while long-read RNA sequencing can characterize complete transcript isoforms and complex splicing patterns. Protein-level methods, such as Western blotting or mass spectrometry, may help establish whether altered transcripts affect the production or structure of proteins.
  • Understanding splicing-associated diseases has important clinical applications. Splicing analysis can improve genetic diagnosis, help classify disease-causing variants, identify disease mechanisms, and support the development of targeted treatments. Antisense oligonucleotides (ASOs) can modify splice-site selection by binding to specific RNA sequences and influencing the recognition of exons or splice sites. Nusinersen, used to treat spinal muscular atrophy, promotes the inclusion of exon 7 in SMN2 transcripts, increasing the production of functional SMN protein. Other therapeutic approaches include small molecules that modify splicing activity, gene therapy, and genome editing. The effectiveness and safety of these approaches depend on the specific disease mechanism, target tissue, and molecular characteristics of the abnormal transcript.
  • In animal genomics and breeding, splicing-associated variation can influence economically important traits, disease susceptibility, growth, reproduction, metabolism, muscle development, milk production, and adaptation. Genetic variants that alter transcript processing may contribute to differences in protein function and gene expression among breeds or individuals. RNA sequencing can help identify alternative splicing patterns associated with production traits, developmental processes, and environmental responses. Integrating genomic variants with transcriptomic and phenotypic data can improve the understanding of functional genetic variation and support the identification of candidate biomarkers. However, splicing differences should be interpreted carefully because they may reflect tissue composition, developmental stage, environmental conditions, or disease consequences rather than directly causing a trait.
  • Despite advances in sequencing technologies and computational prediction, several challenges remain in splicing-associated disease research. Many splicing events are tissue-specific, making it difficult to identify the relevant transcript in an accessible sample. Short-read sequencing may not resolve complex transcript structures or distinguish closely related isoforms. Low-abundance transcripts, incomplete genome annotations, genetic background, and environmental influences can complicate interpretation. In addition, a predicted splicing change does not necessarily produce a clinically important protein alteration. Combining genomic sequencing, RNA sequencing, long-read technologies, computational prediction, and experimental validation provides a more reliable approach to understanding these diseases.
  • Splicing-associated disease research therefore connects molecular genetics, transcriptomics, clinical genomics, and computational biology. Bioinformatics enables researchers to identify splicing-related variants, detect abnormal transcript patterns, investigate molecular mechanisms, and prioritize potential therapeutic targets. As sequencing technologies, transcript annotations, and machine-learning methods continue to improve, the analysis of RNA splicing is expected to become increasingly important in precision medicine, disease diagnosis, and functional genomics.
Author:

Leave a Reply

Your email address will not be published. Required fields are marked *